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INTRODUCTION
Colorectal cancer is a disease with a high inci-
dence and mortality rate, and has been increasing in
prevalence worldwide (1). Therefore, various pre-
vention strategies have been investigated. Primary
prevention attempts to prevent the occurrence of col-
orectal cancer by lifestyle modification, and secon-
dary prevention aims to arrest the progression of
colorectal cancer through early diagnosis and treat-
ment. In addition to these, recently, chemopreven-
tion, the use of oral drugs to prevent cancer, has at-
tracted much attention. Many compounds have been
tested to assess their inhibition of colorectal carcino-
genesis in animal models, and some of them have
been proceeded to clinical trials for chemopreven-
tion.
Recent progress in the molecular analysis of col-
orectal carcinogenesis has revealed many candidate
molecules for chemopreventive agents. In this re-
view, we summarize new findings regarding experi-
mental data and clinical trials for the chemopreven-
tion of colorectal cancer.
ANIMAL MODEL OF COLORECTAL CAN-
CER
It is very important to use an animal model for
the evaluation of chemopreventive agents against
colorectal carcinogenesis. There are two kinds of ro-
dent model for colorectal cancer. One is the model
of chemical carcinogenesis employing carcino-
gens such as azoxymethane, 1, 2-dimethylhydrazine
(DMH), N -ethyl -N’ - nitro -N -nitrosoguanidine
(ENNG), etc. Of these, the azoxymethane model is
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the most widely used as a model of sporadic colorec-
tal carcinogenesis, and is reportedly very similar to
human colorectal cancer in terms of the clinical
symptoms, clinical course, and pathological findings
(2). The other one is the genetic model harboring
gene mutations such as APC, p53, etc. The Min
mouse and Apc delta716 knockout mouse, both of
which have APC mutations, are also used worldwide
(3, 4).
In 1987, Bird reported a tiny lesion consisting of
large, thick crypts in a methylene blue-stained speci-
men of the colon from mice treated with azoxymeth-
ane, and suggested to be a precursor lesion of col-
orectal cancer in the animal model (5). Then, abun-
dant evidence was reported to support that aberrant
crypt foci (ACF) are a precursor lesion of colorectal
cancer. Thus, ACF are often used as a target lesion
to test chemopreventive effects in animal models of
colorectal carcinogenesis.
CHEMOPREVENTIVE AGENTS AND TAR-
GET MOLECULES
Recent progress in the molecular analysis of col-
orectal cancer has made it possible to target a spe-
cific molecule for chemoprevention (6). Many prom-
ising target molecules have been reported so far
(Table 1). These can be mainly classified into 3
categories based on the mechanism : 1) signal trans-
duction modulation, 2) epigenetic modulation, and
3) anti-inflammatory modulation.
1) Signal transduction modulator
The signal transduction pathway has been
searched for a long time as a target of chemotherapy
and chemoprevention. EGF receptor inhibitors (Er-
lotinib, etc.), anti-EGF receptor antibody (Cetuxi-
mab), and anti-VEGF antibody (Bevacizumab) are
well-known as therapeutic agents for cancer and
commonly used worldwide (7). Although these
agents have not yet been applied to chemopreven-
tion, they themselves or their analogues may be put
to practical use as chemopreventive agents of col-
orectal cancer in the future. Since mutations of K-ras
and p53 are frequently observed in colorectal can-
cer, their oncogenic pathway is a possible target.
Anti-ras agents such as Tipifarnib and perilyl alco-
hol, and anti - p53 agents such as CP31398 have
been reported to inhibit colorectal carcinogenesis in
animal models (8). Other signal transduction modu-
lators targeting Bcl-2, ODC, GST-pi, etc., have also
been examined for their chemopreventive effect on
colorectal cancer.
2) Epigenetic modulation
It is well known that peroxisome proliferator-
activated receptor (PPAR)- γ and -δ play a role in the
Table 1 Candidate of chemopreventive agents and target molecules for colorectal cancer
Mechanism Target Agents
Signal transduction EGF receptor Cetuximab, Erlotinib
modulation Bcl -2 ABT-737
Ras Tipifarnib, Perillyl alcohol
p53 CP31398
Matrixmetalloproteinases Marimistat, Prinomastat
ODC DFMO, NSAIDs, Retinoids
VEGF/VEGF receptor Bevacizumab
GST-pi HGBP, TLK119
Epigenetic Peroxisome proliferator Rosiglitazone, Pioglitazone
modulation activated receptor(PPAR)
Vitamin D Vitamin D3 analogue
ER-β Resveratorol, TAS-108
Histone deacetylase SAHA
Retinoic acid receptor Retinoids
Anti - inflammation COX-2 NSAIDs, Celecoxib, Etodorac
EP1- 4 ONO-8711
NF - κB Bortezomib, Curcumin, Tea polyphenols, Statins, NSAIDs
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process of colorectal carcinogensis. Of these, PPAR-γ
agonists such as rosiglitazone and pioglitazone re-
portedly inhibit the formation of colorectal cancer in
animal models (9). Currently, they are being tested
in human trials. There are some studies in which
vitamin D inhibited the development of colorectal
adenoma and cancer. Other epigenetic modulators
including ER-β , histone deacetylase, and retinoic
acid receptor have been reported to be potential che-
mopreventive agents in animal models.
3) Anti-inflammatory modulation
Cyclooxygenase-2 (COX-2) is reportedly overex-
pressed in colorectal adenoma and cancer of ro-
dents and humans. It is also reported that COX-2
promotes the cell growth and inhibits apoptosis of
colorectal epithelia. When an Apc delta716 knock-
out mouse, a model of human familial adenomatous
polyposis, was crossed with a COX-2 knockout
mouse, the number and size of intestinal polyps
were markedly reduced (10). Moreover, there are
many studies showing that selective COX-2 inhibi-
tors suppressed colorectal adenoma and cancer.
Thus, the efficacy of targeting the COX-2 molecule
for chemoprevention was theoretically confirmed
in animal models. There are also many other anti-
inflammatory agents including EP1-4 and NF-κB
currently under investigation.
CLINICAL TRIAL FOR CHEMOPREVEN-
TION
Representative human chemopreventive trials are
shown in Table 2. They are mainly classified into 3
categories according to the target lesion. The first
one is a trial that targets a pre-existing polyp. Giar-
diello, et al. reported that sulindac significantly sup-
pressed the number and size of polyps in familial
adenomatous polyposis patients in 1993 (11). This
study prompted investigators to conduct a trial to ex-
amine whether or not sulindac suppresses sporadic
polyps. However, it did not significantly suppress the
number or size of the polyps (12). This trial revealed
that a pre-existing polyp is not necessarily an appro-
priate target for chemoprevention; a large polyp
close to a cancer may not be able to respond to che-
mopreventive agents. Thus, chemoprevention tar-
geting the development of a new polyp in polypec-
tomized patients was conducted thereafter. Several
randomized trials showed that aspirin inhibited the
development of polyps. Since COX-2 was shown to
be a good target molecule for chemoprevention in
animal experiments, as noted above, two large-scale
randomized clinical trials using a selective COX-2
selective inhibitor (celecoxib) were performed. Ar-
ber, et al. reported that celecoxib (400 and 800 mg/
day) significantly reduced the new development of
Table 2 Representative chemopreventive studies for colorectal cancer
Sporadic/FAP Agents Period Results Author
Pre-existing polyp
FAP Sulindac 4 yr No change Giardiello, et al. (2002)
FAP Celecoxib 6 mo 30% reduction Steinbach, et al. (2000)
Sporadic Sulindac 4 mo No change Ladenheim, et al. (1995)
FAP Sulindac 9 mo 65% reduction Giardiello, et al. (1993)
Development of new polyp
Sporadic Celecoxib 3 yr 38% reduction Bertagnolli, et al. (2006)
Sporadic Celecoxib 3 yr 35% reduction Arber, et al. (2006)
Sporadic Aspirin 1 yr 37% reduction Sandler, et al. (2003)
Sporadic Aspirin 13 yr 17% reduction Baron, et al. (2003)
Sporadic Calcium 4 yr 15% reduction Baron, et al. (1999)
Development of cancer
Sporadic Vitamin D
Calcium
6 yr 32% reduction
No change
Martinez, et al.(1996)
Sporadic Vitamin D
Calcium
4 yr 26% reduction
No change
Bostick, et al. (1993)
Sporadic Folic acid 6 yr 31% reduction Giovannucci, et al. (1993)
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adenoma compared to a placebo group (13). Bert-
agnolli, et al. also reported that celecoxib (400 and
800 mg/day) significantly reduced the development
of adenoma in a different large-scale trial (14). How-
ever, in these trials, severe cardiovascular events in-
cluding myocardial infarction and stroke occurred
in about 20% of cases. Therefore, it is considered
that the COX-2 inhibitor is an effective agent for the
prevention of colorectal cancer, but it cannot be rec-
ommended for chemoprevention because of poten-
tial cardiovascular events.
The third one is a trial that targets the develop-
ment of cancer. This kind of trial is theoretically
ideal because it examines if each agent indeed sup-
presses the development of cancer itself. However,
it takes more than 4 years, and prolongation of the
trial sometimes causes severe side effects and poor
compliance.
CHEMOPREVENTION TARGETING ACF
Since ACF are the earliest precursor lesions of
colorectal cancer (15, 16), they would be an appro-
priate target for chemoprevention (Fig. 1). The ad-
vantages of using ACF as targets over a polyp and
cancer are as follows : (1) short-term treatment for
evaluation, (2) fewer complications caused by drugs,
and (3) good compliance. Thus, we performed an
open trial in which sulindac was administered for
various periods to subjects positive for ACF. The re-
sults showed that the majority of ACF were eradi-
cated after only a few months. Based on this, we
next performed a randomized double-blind trial tar-
geting ACF consisting of groups receiving sulindac,
etodolac (a selective COX-2 inhibitor), or a placebo.
The detailed results of this study will be clarified in
the near future.
EPILOGUE
Many candidate agents for chemoprevention are
currently being tested, and some of them have ac-
tually shown potential chemopreventive activity in
human trials. Although the COX-2 inhibitor failed
to be a major chemopreventive agent, other effective
new agents will be identified in the near future.
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